Levocarnitine en es it fr

Levocarnitine Brand names, Levocarnitine Analogs

Levocarnitine Brand Names Mixture

  • No information avaliable

Levocarnitine Chemical_Formula


Levocarnitine RX_link


Levocarnitine fda sheet

Levocarnitine FDA

Levocarnitine msds (material safety sheet)

Levocarnitine MSDS

Levocarnitine Synthesis Reference

No information avaliable

Levocarnitine Molecular Weight

161.199 g/mol

Levocarnitine Melting Point

196-197 oC

Levocarnitine H2O Solubility

2500 mg/mL

Levocarnitine State


Levocarnitine LogP

No information avaliable

Levocarnitine Dosage Forms

Liquid; Solution; Tablet

Levocarnitine Indication

For treatment of primary systemic carnitine deficiency, a genetic impairment of normal biosynthesis or utilization of levocarnitine from dietary sources, or for the treatment of secondary carnitine deficiency resulting from an inborn error of metabolism such as glutaric aciduria II, methyl malonic aciduria, propionic acidemia, and medium chain fatty acylCoA dehydrogenase deficiency. Used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias. Parenteral levocarnitine is indicated for the prevention and treatment of carnitine deficiency in patients with end-stage renal disease.

Levocarnitine Pharmacology

Levocarnitine is a carrier molecule in the transport of long chain fatty acids across the inner mitochondrial membrane. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Lack of carnitine can lead to liver, heart, and muscle problems. Carnitine deficiency is defined biochemically as abnormally low plasma concentrations of free carnitine, less than 20 µmol/L at one week post term and may be associated with low tissue and/or urine concentrations. Further, this condition may be associated with a plasma concentration ratio of acylcarnitine/levocarnitine greater than 0.4 or abnormally elevated concentrations of acylcarnitine in the urine. Only the L isomer of carnitine (sometimes called vitamin BT) affects lipid metabolism. The "vitamin BT" form actually contains D,L-carnitine, which competitively inhibits levocarnitine and can cause deficiency. Levocarnitine can be used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.

Levocarnitine Absorption

Absolute bioavailability is 15% (tablets or solution).

Levocarnitine side effects and Toxicity

LD50 > 8g/kg (mouse, oral). Adverse effects include hypertension, fever, tachycardia and seizures.

Levocarnitine Patient Information

Levocarnitine Organisms Affected

Humans and other mammals